Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584 | Completed Phase 3 Results

• 2 other identifiers: 917822009-009598-90
• Study Type: interventional
• Target: 460
• Locations: 9 countries
• Sites: 48

Brief Summary

The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of the breasts) may benefit from MRI of the breasts as MRI may detect additional breast cancers

Conditions

Breast Cancer

Keywords

Breast Cancer; Gadobutrol-enhanced MRI; Mammography; Diagnostic Imaging

Outcome Measures

Primary Outcomes (3)

• Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader

  For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the clinical investigators and the 3 blinded readers using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants. The difference was calculated as CMRM value minus UMRM value. For ease of expression, the following abbreviations will be used: Magnetic Resonance Mammography (MRM), Unenhanced MRM (UMRM), combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM), X-ray mammography (XRM).

  Immediately before injection and after injection

• Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader

  For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the clinical investigators and the 3 blinded readers using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants.

  Immediately before injection and after injection

• Breast Level Specificity of CMRM for Non-malignant Breasts by Reader

  A non-malignant breast was defined as false positive (FP), when the reader assessed at least one breast region as malignant. When all breast regions were assessed as non-malignant, the breast was defined as true negative (TN). Breast level specificity was first defined in participant as number of TN-breasts in participant divided by number of non-malignant breasts in participant. Subsequently the specificity percentage was calculated based on the mean of the specificities across all participants who contributed with at least one non-malignant breast.

  Immediately before injection and after injection

Secondary Outcomes (4)

• Breast Level Specificity of CMRM Based on Malignant Breasts

  Immediately before injection and after injection

• Percentage Difference of Participants Whose Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM

  Immediately before injection and after injection

• Percentage Difference of Participants Whose Additional Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM

  Immediately before injection and after injection

• Difference of Confidence in Diagnosis for Breast Region Diagnosis Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM and CMRM+XRM vs XRM by Reader, Participant Level

  Immediately before injection and after injection

Other Outcomes (21)

• Sensitivity for Detection of Full Extent of Malignant Breast Disease Using XRM, CMRM+XRM and UMRM+XRM Per Reader

  Immediately before injection and after injection

• Breast Level Specificity of in Non-malignant Breasts Using UMRM, XRM, CMRM+XRM and UMRM+XRM by Reader

  Immediately before injection and after injection

• Breast Level Specificity in Malignant Breasts Using UMRM, XRM, CMRM+XRM and UMRM+XRM by Reader

  Immediately before injection and after injection

Study Arms (1)

Gadobutrol (Gadavist, BAY86-4875)

EXPERIMENTAL

Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) \[0.1 ml/kg bw\] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.

Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)

Interventions

Gadobutrol (Gadavist, Gadovist, BAY86-4875) DRUG

A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight

Gadobutrol (Gadavist, BAY86-4875)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology \[ACR\] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced Magnetic Resonance Mammography (MRM) prior to surgery of the breast.
• if female, a digital XRM is required if any of the following criteria is met:
• a. patient is younger than 50 years;
• b. patient has heterogeneously or extremely dense breasts;
• if female of childbearing potential, MRM should be performed on the 7-14th day of the menstrual cycle.
• has an estimated glomerular filtration rate (eGFR) value \>/= 60 mL/min/1.73m\^2 derived from a serum creatinine result within 2 weeks prior to study enrollment.

You may not qualify if:

• is a female patient who is pregnant or lactating
• has any contraindication to the MRM examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents.
• has received any contrast agent within 24 hours prior to the study MRM, or is scheduled to receive any contrast agent within 24 hours after the study MRM.
• has severe cardiovascular disease (e.g., known long QT syndrome, acute myocardial infarction \[\< 14 days\], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (\< 48 hours)).
• has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate \< 60 mL/min/1.73m\^2).
• has received chemotherapy or hormonal therapy for breast cancer within 6 months.
• has received hormone replacement therapy within 4 weeks prior to study drug administration.
• is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application
• has prior excisional biopsy or breast surgery less than 6 months before enrollment and between XRM and study MRM

Sponsors & Collaborators

• Bayer: lead

Study Sites (48)

Unknown Facility

Tucson, Arizona, 85724, United States

Location

Unknown Facility

Oakland, California, 94609, United States

Location

Unknown Facility

Englewood, Colorado, 80112, United States

Location

Unknown Facility

Chicago, Illinois, 60637, United States

Location

Unknown Facility

New York, New York, 10065, United States

Location

Unknown Facility

Columbus, Ohio, 43212, United States

Location

Unknown Facility

Providence, Rhode Island, 02903, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Tacoma, Washington, 98321, United States

Location

Unknown Facility

Buenos Aires, Ciudad Auton. de Buenos Aires, C1082A, Argentina

Location

Unknown Facility

Buenos Aires, Ciudad Auton. de Buenos Aires, C1181ACH, Argentina

Location

Unknown Facility

Buenos Aires, Ciudad Auton. de Buenos Aires, C1425BEE, Argentina

Location

Unknown Facility

Hamilton, Ontario, L8N 4A6, Canada

Location

Unknown Facility

Toronto, Ontario, M5G 2M9, Canada

Location

Unknown Facility

Toronto, Ontario, M5S 1B2, Canada

Location

Unknown Facility

Montreal, Quebec, H4J 1C5, Canada

Location

Unknown Facility

Erlangen, Bavaria, 91054, Germany

Location

Unknown Facility

München, Bavaria, 81377, Germany

Location

Unknown Facility

Frankfurt am Main, Hesse, 60596, Germany

Location

Unknown Facility

Göttingen, Lower Saxony, 37081, Germany

Location

Unknown Facility

Göttingen, Lower Saxony, 37099, Germany

Location

Unknown Facility

Greifswald, Mecklenburg-Vorpommern, 17489, Germany

Location

Unknown Facility

Bochum, North Rhine-Westphalia, 44892, Germany

Location

Unknown Facility

Münster, North Rhine-Westphalia, 48145, Germany

Location

Unknown Facility

Münster, North Rhine-Westphalia, 48149, Germany

Location

Unknown Facility

Gera, Thuringia, 07548, Germany

Location

Unknown Facility

Berlin, 10115, Germany

Location

Unknown Facility

Mumbai, Maharashtra, 400012, India

Location

Unknown Facility

Delhi, 110085, India

Location

Unknown Facility

Mumbai, 400 004, India

Location

Unknown Facility

Eindhoven, EJ, 5623, Netherlands

Location

Unknown Facility

Maastricht, 6229 HX, Netherlands

Location

Unknown Facility

Nijmegen, 6525 GA, Netherlands

Location

Unknown Facility

Bydgoszcz, 85-796, Poland

Location

Unknown Facility

Gliwice, 44-100, Poland

Location

Unknown Facility

Krakow, 30-501, Poland

Location

Unknown Facility

Szczecin, 70-111, Poland

Location

Unknown Facility

Warsaw, 02-781, Poland

Location

Unknown Facility

Barcelona, Barcelona, 08036, Spain

Location

Unknown Facility

Sabadell, Barcelona, 08208, Spain

Location

Unknown Facility

Girona, Girona, 17002, Spain

Location

Unknown Facility

Alzira, Valencia, Spain

Location

Unknown Facility

Córdoba, 14004, Spain

Location

Unknown Facility

Taipei, Taiwan, 100, Taiwan

Location

Unknown Facility

Taichung, Taiwan

Location

Unknown Facility

Taipei, 110, Taiwan

Location

Unknown Facility

Taipei, 114, Taiwan

Location

Unknown Facility

Taizung, 402, Taiwan

Location

Related Publications (2)

• Endrikat J, Schmidt G, Haverstock D, Weber O, Trnkova ZJ, Barkhausen J. Sensitivity of Contrast-Enhanced Breast MRI vs X-ray Mammography Based on Cancer Histology, Tumor Grading, Receptor Status, and Molecular Subtype: A Supplemental Analysis of 2 Large Phase III Studies. Breast Cancer (Auckl). 2022 Apr 19;16:11782234221092155. doi: 10.1177/11782234221092155. eCollection 2022.

  PMID: 35462754 DERIVED

• Sardanelli F, Newstead GM, Putz B, Jirakova Trnkova Z, Trimboli RM, Abe H, Haverstock D, Rosenberg M. Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies. Invest Radiol. 2016 Jul;51(7):454-61. doi: 10.1097/RLI.0000000000000254.

  PMID: 26840494 DERIVED

Related Links

• Click here and search for information of Bayer products for Europe

MeSH Terms

Conditions

Breast Neoplasms

Interventions

gadobutrol

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Therapeutic Area Head
• Organization: BAYER

clinical-trials-contact@bayerhealthcare.com

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2010
• First Posted: April 15, 2010
• Study Start: May 1, 2010
• Primary Completion: September 1, 2011
• Study Completion: January 1, 2012
• Last Updated: November 11, 2014
• Results First Posted: November 11, 2014

Record last verified: 2014-11

Locations

IN (3); PL (5); US (9); CA (4); AR (3); NL (3); ES (5); TW (5); DE (11)